BioSpace News Archive

Surgical robots are witnessing extensive use by doctors to assist in minimally invasive surgeries to reduce recovery time, uneasiness, and prolonged pain in patients.

Catapult Therapeutics, a biopharmaceutical company developing novel cancer treatments, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its lead product candidate CAP-100

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced the appointment of Scott Waldman as senior vice president, corporate development, for AMRI.

Global ventricular assist devices market share is expected to witness significant gains over 2019-2025, driven by the escalating cases of heart failure and shortage of heart donors worldwide.

TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 58,333,334 shares of common stock, par value $0.001 per share at an offering price of $1.20 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.

Urine biomarker test will provide healthcare practitioners with a highly accurate, non-invasive tool to identify and monitor rejection and elevated risk of rejection in kidney transplant patients.

Cerebro Global, a leading authority in healthcare research, launched its new strategic 2021 leadership advance initiative READY FORWARD, focusing on providing healthcare clients exceptional research support and guidance for development and commercialization efforts through the evolving global market forces and factors.

The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple platform-generated products in advanced-stage: endometrial cancer, ovarian cancer, angiosarcoma, and B-Cell lymphomas Study LS1681 is a Mayo Investigator-Initiated-Trial (IIT) for relapsed or refractory B-cell lymphomas; and is evaluating rituximab-ADNAB™

InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million,

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2020 financial results will be reported after the market closes on Tuesday, March 16.